Menu

Avapritinib (Ayvakit) Prescribing Information: Indications, Dosage, Adverse Reactions and Safety Warnings

Author: medicalhalo
Release time: 2026-11-16 02:36:53

  Avapritinib(Ayvakit)is a potent selective inhibitor of PDGFRαand c‑Kit.It suppresses ligand‑independent autophosphorylation of mutant receptors including PDGFRαD842V and c‑Kit D816V,inhibiting tumor cell proliferation.Genetic testing,platelet count and pregnancy screening are required prior to initiation.

  Indications

  Gastrointestinal Stromal Tumor(GIST):Unresectable or metastatic GIST harboring PDGFRαexon 18 mutations(including D842V)in adults.Mutation must be confirmed by PCR or NGS before treatment;suitable for imatinib‑resistant disease.

  Advanced Systemic Mastocytosis(AdvSM):Adult patients with aggressive systemic mastocytosis(ASM),SM‑AHN,or mast cell leukemia(MCL).

  Indolent Systemic Mastocytosis(ISM):Adult clonal mast cell disorder,mostly driven by KIT D816V mutation.

  Dosage and Administration

  Oral administration,once daily on an empty stomach(at least 1 hour before or 2 hours after meals).If a dose is missed,take it as soon as remembered if≥8 hours remain before next scheduled dose.Do not re‑dose after vomiting;take next dose at regular time.

  GIST:300mg once daily;permanently discontinue if 100mg daily is not tolerated.

  AdvSM:200mg once daily;permanently discontinue if 25mg daily is not tolerated.

  ISM:25mg once daily.

  Dose reduction schedule:GIST reduce to 200mg,then 100mg sequentially;AdvSM reduce to 100mg,50mg,then 25mg.Permanently discontinue for any grade intracranial hemorrhage.Manage cognitive adverse effects by holding,reducing or permanently stopping based on severity.For AdvSM,withhold therapy when platelets<50,000/mm³and resume at reduced dose after recovery.

  Pretreatment Screening and Monitoring

  Confirm PDGFRαexon 18 mutation before GIST treatment.Avapritinib is contraindicated in AdvSM/ISM patients with baseline platelets<50,000/mm³.For AdvSM,monitor platelet counts every 2 weeks during the first 8 weeks;subsequent frequency depends on platelet levels.Closely monitor all patients for signs of intracranial hemorrhage(headache,vomiting,altered mental status,etc.).

  Adverse Reactions

  Common reactions in GIST:edema,nausea,fatigue,cognitive impairment,vomiting,decreased appetite,diarrhea,hair color changes.AdvSM:edema,diarrhea,nausea,fatigue.ISM:periorbital edema,dizziness,peripheral edema,flushing.Key severe risks include intracranial hemorrhage,CNS cognitive toxicity and photosensitivity.

  Precautions

  Intracranial hemorrhage can be fatal.Higher risk in patients with cerebrovascular disease,aneurysms,thrombocytopenia or concomitant anticoagulants.Seek medical care immediately if symptoms appear.CNS effects may impair driving or operating machinery.Avoid direct UV exposure during treatment and 1 week after discontinuation.Embryo‑fetal toxicity present;effective contraception is required for 6 weeks after last dose.Discontinue breastfeeding during therapy and for 2 weeks after final dose.

  Special Populations

  No dose adjustment for mild or moderate hepatic impairment.For severe hepatic impairment(Child‑Pugh C):GIST 200mg daily,AdvSM 100mg daily,ISM 25mg every other day.No adjustment for mild/moderate renal impairment;no data for severe renal disease.No specific dose change for elderly;safety in pediatric patients is not established.

  Drug Interactions

  Metabolized primarily via CYP3A4/3A5.Avoid concomitant strong or moderate CYP3A inhibitors or inducers.If moderate CYP3A inhibitor is unavoidable,reduce GIST dose to 100mg daily and AdvSM dose to 50mg daily.Rifampin and efavirenz markedly reduce exposure and are contraindicated.Azole antifungals substantially increase avapritinib exposure.

  Storage

  Store at 20°C–25°C;excursions permitted between 15°C and 30°C.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。